Objective. The goal of the present study was to estimate the treatment costs in immune-mediated rheumatic disease patients initiating treatment with an s.c. biologic agent based on treatment persistence.
Introduction
AS, PsA and RA are chronic progressive immunemediated rheumatic diseases (IMRDs) that can cause pain, deformity and disability and progressively impair joint structure and function [1] . IMRDs result in substantial personal as well as economic burden [2] .
The primary treatment goal for all three conditions is to maximize health-related quality of life by controlling symptoms and inflammation, preventing progressive structural damage, preserving or normalizing function and social participation and targeting remission. Treatment of rheumatic diseases usually involves a multimodal approach including both pharmacological and non-pharmacological strategies [3, 4] . The advent of biologic medications such as s.c. TNF-a inhibitors (TNFis) has transformed the management of IMRDs [5] . Previous research has provided high-quality evidence that anti-TNF agents improve clinical symptoms in the treatment of IMRDs [68] .
Taking the prescribed medication for a sufficient period of time is crucial to the success of any therapy. Noncompliance and a lack of persistence with prescription medications are major problems in the clinical management of chronic diseases and s.c. TNFi treatment is potentially a very convenient option for patients. However, patients may likely have drug interruptions or long periods of non-persistence. In IMRDs, treatment persistence can be used to represent drug effectiveness, safety and treatment satisfaction [911] .
While associations between adherence and costs [12] and the cost impact of switching from an s.c. TNFi to different biologic classes have been examined [5, 13] , studies estimating the cost impact of non-persistence in patients treated with s.c. TNFis for IMRDs are lacking. In 2016, Dalé n et al. [14] analysed treatment costs in first-line (bio-naïve) IMRD patients in Sweden based on persistent and non-persistent patients. The results of their study indicated that persistence with s.c. TNFi treatment may be associated with some cost offsets for IMRD patients. In 2017, Dalé n et al. [15] further showed that, in second-line therapy with s.c. TNFis, persistent patients had lower mean total costs. In the same year, Svedbom et al. [16] described and compared treatment persistence with firstand second-line s.c. TNFis as well as their corresponding costs in Sweden.
Although these works are of great interest, no recent data are available about the association between non-persistence with s.c. TNFis and costs in Germany. The goal of the present study was to estimate and compare the direct and indirect treatment costs in IMRD patients initiating treatment with an s.c. biologic agent based on treatment persistence.
Methods

Data source
This study is a retrospective cohort study based on the German statutory health insurance funds database. This database continuously provides data pertaining to about five million statutorily insured people, which corresponds to 7% coverage. Exclusively anonymous information and no personal data (in accordance with § 3 Abs. 6 German Federal Data Protection Act) are used. Each patient with defined characteristics (e.g. specific disease, number and/or durations of hospitalizations, prescriptions of specific medications or any combination of these characteristics) can be tracked within the database via a unique patient ID. Finally, the database has already been used in several epidemiological studies, including cost analyses [17] .
General informed consent
Informed patient consent
German law allows the use of anonymous electronic medical records for research purposes under certain conditions. Because patients were only queried as aggregates and no protected health information was available for queries, no institutional review board approval was required for the use of this database or completion of this study.
For this study, we only used anonymized data collected from the claims database. Therefore, this study does not require that we obtain informed consent from patients. The date of the first qualifying prescription for an s.c. biologic agent served as the patient's index date. The 12-month period immediately preceding the index date was used as the pre-index period and the 12-month period following the final prescription within the persistence period served as the post-index period, which lasted no later than December 2015. All patients were traceable in the database for at least 12 months after their last prescription within the analysis period. The pre-index period and index date were used to measure patients' baseline characteristics. Treatment persistence with index s.c. TNF-a blockers and health care resource utilization (such as services and direct and indirect costs) were evaluated in both the persistence and post-index periods.
Study population
Persistence definition and patient stratification
Persistence was defined as the duration of time from s.c. TNFi therapy initiation to discontinuation, which was identified as at least 60 days without s.c. TNFi therapy. A longitudinal dataset of medication supply was created for each individual patient and the number of days of drug supply was calculated based on the defined daily dose information associated with each prescription record. The persistence was evaluated at 24 months after the index date. Following this estimation of persistence, patients were categorized into persistent and non-persistent cohorts.
The main outcome of the study was rheumatoid diseaserelated health care resource utilization costs, including direct costs and services. These costs were estimated for the time within 2 years (730 days) following the first s.c. TNFi prescription and separated by RA, PsA and AS indication. Direct costs included hospitalization costs, doctor and hospital visit costs, prescribed medication costs and sickness benefits (in Germany, sickness funds are obligated to provide sick pay for sick leaves of at least 43 days). Services consisted of the number of hospital stays, duration of hospitalization, medical department of the hospital involved and specialties visited.
Covariates
Demographic characteristics of patients at the index date included age (as a continuous variable and age groups) and gender. Further baseline variables were year of index date and the specialty of the physician initiating treatment. Furthermore, a revised version of the Charlson comorbidity index (CCI) was used as a generic marker of comorbidity.
Statistical methods
To control for confounding, 1:1 matching was carried out based on a propensity score that was constructed as the conditional probability of being persistent as a function of age, gender, index year, physician specialty and CCI (logistic regression). Greedy matching was used by choosing a non-persistent patient whose propensity score was closest to that of this randomly selected persistent subject for matching. Descriptive statistics were given and group differences (persistent vs non-persistent) were assessed using the Wilcoxon test or the McNemar's tests after propensity score matching. Finally, the differences in direct costs, indirect costs and services between matched pairs were estimated using the Wilcoxon test.
Results
Patient characteristics
A total of 2060 patients initiating s.c. TNFi therapy were included in the study. After 2 years of follow-up, 682 patients still received s.c. TNFi therapy and 1378 patients had discontinued therapy. In the cohort of non-persistent patients, the mean persistence duration was 266 days (S.D. 190). We observed no significant difference between persistent and non-persistent patients in terms of age, gender or year of therapy initiation. Non-persistent patients had a slightly worse average health status compared with the persistent cohort (CCI 2.6 vs 2.4) ( Table 1 ). After 1:1 matching, 678 pairs (678 persistent and 678 non-persistent patients) were available for cost analyses. Both cohorts were similar in terms of age, gender, year of therapy initiation, CCI and indication (Table 1) . Table 2 shows the mean per-patient costs in the persistent and non-persistent cohorts. The costs for office-based visits per patient were E2319 in the persistent cohort and E3094 in the non-persistent cohort (P < 0.001). The cost difference was the highest in the mixed indication group (Table 2 ). An average persistent patient received prescriptions of different co-medications worth E2828 and a nonpersistent patient received prescriptions worth E5498 within the 2-year time period (P < 0.001). In this category, the highest cost difference was found for patients with RA. Hospitalization costs were E3551 per persistent patient and E5890 per non-persistent patients (Table 2) , which was probably due to the longer average duration of hospitalization in the non-persistent cohort. Furthermore, sick leave costs were much lower in persistent (E717) vs nonpersistent (E1241) patients. Total costs per patient (excluding the cost of s.c. TNFi therapy) were $E6634 lower in the persistent cohort (Table 2) .
Cost analyses
However, as expected, when including the cost of s.c. TNFi prescriptions, the total cost per patient was higher in the persistent cohort than in the non-persistent cohort ( Table 2) .
Discussion
This retrospective study of 1356 patients found that the 2-year costs per patient for office-based visits, hospitalizations, co-medications and sick leave costs were higher in patients who discontinued their s.c. TNFi therapy after an average of 9 months compared with patients with at least 24 months of therapy. Moreover, the average duration of hospitalization was longer in non-persistent patients.
Since the database used does not include data on symptoms and diagnosis severity, costs can be used as a surrogate parameter for patients' health status. Evidence regarding the share of patients who continued to do well after discontinuation of anti-TNF therapy is lacking. However, even if only some patients who discontinue s.c. TNFi therapy experience an increase in disease activity, this can result in more physician visits, longer hospitalizations and more days of sick leave. On the one hand, this can be caused by the IMRD symptoms themselves. On the other hand, increased time-averaged disease activity in RA can be associated with a higher risk of cardiovascular events [18] as well as a higher probability of developing infections [19] . The difference in non-TNF medication in our study was $54%, which is in line with results of Dalen et al. [14] who reported a difference of 56%.
Regardless of the diagnosis, but especially in the case of diseases accompanied by pain, better persistence and greater adherence is associated with a considerable reduction in cost. This does not refer to total costs but rather to co-therapy and hospitalizations. Therefore such cost savings provide indirect but clear evidence regarding quality of life. TNFi products are relatively costly and patients with longer treatment durations, that is, better persistence, receive a greater number of prescriptions, which leads to higher treatment costs, while at the same time reducing other costs (co-therapies, hospital, service utilization, sick leave costs). However, longer therapy can achieve an improvement in the quality of life of IMRD patients. Moreover, the value of good persistence can be considered in terms of benefits to all participants in the health care system, including health care providers and payers.
Study limitations
Each retrospective study is limited by the availability of data in this database. The specific markers or tests of disease severity and the reasons for discontinuation are not recorded in the database. Furthermore, analyses are based on data of the Betriebskrankenkasse insurance fund, which is only one of many insurance funds in Germany, and the patient characteristics of different funds may vary. Moreover, no privately insured patients are included in the analyses. Finally, this study used mean values for costs per patient. However, mean values are highly sensitive to outliers. In this study, service utilization costs in patients with AS were E1011 (S.D. 2478) in nonpersistent and E2326 (S.D. 9589) in persistent patients, due to some outliers with very high costs in persistent patients. On the other side, the median costs were higher in non-persistent vs persistent patients (E262 vs E200), showing the role of outliers. The same statistical effect of outliers can be observed in office-based visit costs of patients with PsA.
Conclusion
The results of this study indicate that persistence with s.c. TNFi treatment can be associated with several cost offsets for IMRD patients, with an improvement in their quality of life. For health care providers and payers, these findings reinforce the value of persistence, given the additional economic burden associated with non-persistent patients.
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